Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

5.700 +0.030 (+0.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 505,522
Open 5.640
Bid (Size) 5.660 (13)
Ask (Size) 5.920 (1)
Prev. Close 5.670
Today's Range 5.585 - 5.780
52wk Range 3.895 - 14.67
Shares Outstanding 54,532,614
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire

Performance

YTD
-31.0%
-31.0%
1 Month
+24.2%
+24.2%
3 Month
-43.8%
-43.8%
6 Month
-39.9%
-39.9%
1 Year
-39.2%
-39.2%

More News

Read More
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tuesday's session: gap up and gap down stocks
Via Chartmill
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
H&E Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
From ORIC Pharmaceuticals
Via GlobeNewswire
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Via MarketBeat
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From ORIC Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Oric Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Oric Pharmaceuticals, Inc. - Common Stock trade on?
Oric Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock is ORIC on the Nasdaq Stock Market
What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?
The current price of Oric Pharmaceuticals, Inc. - Common Stock is 5.700
When was Oric Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 05/05/25 04:00 PM ET
What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 310.84M
How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?
Oric Pharmaceuticals, Inc. - Common Stock has 311M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.